eCOA, eConsent solution elevates patient experience, data quality

uMotif and ClinOne announced at the Drug Information Association (DIA) Global Annual Meeting​, taking place in Chicago June 19-23) their partnership to create an integrated solution to deliver electronic clinical outcome assessments (eCOA) and electronic informed consent (eConsent) technology. The technology is intended to support decentralized clinical trials (DCTs), site-based studies, and hybrid trials of any scale and for any therapeutic area.

uMotif and ClinOne reportedly built their platforms with extensibility and intuitive user experiences in mind, offering flexibility to support different study types. According to the partners, the combined offering is cost-efficient, quick to deploy, and easy for participants to use on their own mobile devices.

“It is encouraging and refreshing to see so many sponsors and CROs adopt patient-first technologies like eCOA and eConsent, but too often they are frustrated by disjointed solutions that place a high burden on users and limit effectiveness,​” said Steve Rosenberg, CEO of uMotif. “Together, uMotif and ClinOne are setting out to directly address these pain points with a seamless and comprehensive solution that trial participants actually want to use. In this way, we will add immediate value to increase data quality and reduce risk while improving convenience and comfort for everyone involved with the trial​.”

uMotif’s eCOA and engagement platform reportedly improves participant experience, transforming the reliability of patient-reported and site-based endpoint data used for new drug approval decisions. eConsent on ClinOne’s adaptive experience platform is said to reduce the risk of consent-related errors and enables more informed participation decisions, providing seamless participant experience across a wide array of therapeutic areas and trial designs.

“The work our customers do to save and improve lives is nothing short of inspiring, and as a technology ecosystem we share a responsibility to provide the patients, caregivers, and sites in their trials with the best experience possible,​” said Andrea Valente, ClinOne CEO. “Yet with the pandemic especially, too many untested products entered the market before they were ready from a user perspective​.”

“With this partnership, our expanded platform continues to provide essential solutions that blend trial activities into the flow of everyday lives and make it easier for everyone to participate in a study​,” Valente added.

uMotif and ClinOne are participating in the DIA Global Annual Meeting, taking place June 19-23 in Chicago. Read here for more information or to attend.​       ​